Aprocitentan Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 12.5 mg
Reference Brands: Tryvio (USA), Jeraygo (EU)
Category:
Hypertension
Aprocitentan is available in Tablets
and strengths such as 12.5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aprocitentan is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aprocitentan can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Aprocitentan (ACT-132577) is an orally active, dual endothelin-1 (ET-1) receptor antagonist that blocks ET-1 binding to both ETA and ETB receptors. It is the active metabolite of macitentan, an orphan drug used in pulmonary arterial hypertension, and is highly bound to plasma proteins with elimination via urine and feces. Aprocitentan is well tolerated at single doses up to 600 mg and multiple doses up to 100 mg once daily, with a half-life of approximately 44 hours, supporting convenient once-daily dosing. Its pharmacokinetic profile shows only minor variations across sex, age, renal function, and fed or fasted conditions.
In patients with resistant hypertension, Aprocitentan has demonstrated significant blood pressure reductions within 14 days, and its effects are enhanced when combined with other antihypertensives, including renin-angiotensin-system blockers. The drug has shown consistent efficacy in ambulatory blood pressure monitoring, aligning with surrogate markers for reduced cardiovascular risk. Currently under investigation in the PRECISION Phase III trial, Aprocitentan holds promise as a novel therapy for treatment-resistant hypertension, potentially expanding the antihypertensive options and providing broader cardiovascular protection for patients whose blood pressure remains uncontrolled despite standard therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing